Firsthand Technology Value Fund Inc Stock Price, News & Analysis

Firsthand Technology Value Fund (NASDAQ: SVVC) reported its top five investments as of August 31, 2022, totaling approximately $47 million, or $6.82 per share. These holdings, which include IntraOp Medical Corp., Wrightspeed, Hera Systems, Revasum, and EQX Capital, account for 93.7% of its total investments. IntraOp Medical represents 34.8%, while Wrightspeed follows closely at 34.1%. A detailed financial report will be released in November 2022, outlining performance metrics and changes since June 30, 2022.

As of July 31, 2022, Firsthand Technology Value Fund (NASDAQ: SVVC) reported its top five holdings, representing 93.2% of estimated total investments of approximately $50.2 million, or $7.28 per share. Key holdings include:

• IntraOp Medical (32.6%)
• Wrightspeed (31.4%)
• Revasum (15.8%)
• Hera Systems (11.2%)
• EQX Capital (2.3%)

The Fund focuses on investments in technology and cleantech companies.

Firsthand Technology Value Fund (NASDAQ: SVVC) announced that Hera Systems, a holding since 2015, will provide spacecraft for the U.S. Space Force's Tetra-5 program. This program aims to develop a prototype constellation for on-orbit refueling and autonomous collaboration. The contract, awarded to Orion Space Solutions, could total $44.5 million if fully exercised. Hera Systems will deliver advanced spacecraft and software for the mission.

Firsthand Technology Value Fund (NASDAQ: SVVC) reported its financial results for Q2 2022, revealing net assets of approximately $49.8 million or $7.22 per share, down from $87.4 million or $12.68 per share as of March 31, 2022. The Fund's total investment loss was about $3.8 million, leading to a net investment loss of approximately $4.5 million. Realized and unrealized losses on investments reached $33.1 million during the quarter. The Fund continues to manage its portfolio actively to enhance performance.

Firsthand Technology Value Fund (NASDAQ: SVVC) reported a preliminary NAV of $7.22 as of June 30, 2022. The Fund's top five holdings—IntraOp Medical, Wrightspeed, Revasum, Hera Systems, and Pivotal Systems—constitute 92.4% of its net assets. IntraOp Medical leads with 32.8% of net assets, while Wrightspeed follows with 30.7%. Total investments stood at $49.3 million or $7.16 per share. The complete financials will be part of the quarterly report in August 2022.

As of May 31, 2022, Firsthand Technology Value Fund (NASDAQ: SVVC) reported its top five holdings, which comprise 92.4% of its estimated total investments of approximately $66.8 million. These include IntraOp Medical (32.2%), Wrightspeed (28.5%), Revasum (17.5%), Hera Systems (9.4%), and Pivotal Systems (4.9%). The Fund's estimated value per share stands at $9.70, with cash and equivalents at approximately $0.27 per share. A comprehensive financial report will be available in August 2022.

The Firsthand Technology Value Fund (NASDAQ: SVVC) announced its top five holdings as of April 30, 2022, comprising IntraOp Medical, Revasum, Wrightspeed, Hera Systems, and Pivotal Systems, which collectively account for 95.5% of the Fund's estimated total investments of approximately $72.3 million, or $10.50 per share. Major investments include 26.9% in IntraOp Medical and 26.8% in Revasum. The Fund focuses on technology and cleantech sectors, and complete financial statements will be available in a quarterly report in August 2022.

Firsthand Technology Value Fund (NASDAQ: SVVC) reported its Q1 2022 financial results, showing net assets of approximately $87.4 million ($12.68 per share), down from $94.8 million ($13.75 per share) at year-end 2021. The Fund's portfolio, including public and private securities, was valued at $82.2 million ($11.93 per share). During Q1, the Fund recorded $1.9 million in investment income, with a net investment income of $1.2 million. However, it suffered net realized and unrealized losses amounting to approximately $8.6 million.

As of March 31, 2022, Firsthand Technology Value Fund (NASDAQ: SVVC) reported a preliminary NAV of $12.68. The Fund's top five holdings include Revasum, IntraOp Medical, Wrightspeed, Hera Systems, and Pivotal Systems, constituting 90.4% of its preliminary net assets. Total investments were $82.2 million, or approximately $11.93 per share. The Fund emphasizes investing in technology and cleantech companies, aiming for long-term capital growth. A full quarterly report will be available in May 2022.